Jalanka Jonna, Lam Ching, Bennett Andrew, Hartikainen Anna, Crispie Fiona, Finnegan Laura A, Cotter Paul D, Spiller Robin
Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Nottingham Digestive Diseases Center and NIHR Nottingham Biomedical Research Center at Nottingham University Hospitals NHS Trust, the University of Nottingham, Nottingham, Notts, UK.
J Neurogastroenterol Motil. 2021 Apr 30;27(2):279-291. doi: 10.5056/jnm20205.
BACKGROUND/AIMS: Diarrhea-predominant irritable bowel syndrome (IBS-D) has been previously associated with evidence of immune activation and altered microbiota. Our aim is to assess the effect of the anti-inflammatory agent, mesalazine, on inflammatory gene expression and microbiota composition in IBS-D.
We studied a subset of patients (n = 43) from a previously published 12-week radomized placebo-controlled trial of mesalazine. Mucosal biopsies were assessed by immunohistochemistry and reverse transcription-polymerase chain reaction for a range of markers of inflammation, altered permeability, and sensory receptors including Toll-like receptors (TLRs) at randomization after treatment. All biopsy data were compared to 21 healthy controls. Patient's stool microbiota composition was analysed through 16S ribosomal RNA sequencing.
We found no evidence of increased immune activation compared to healthy controls. However, we did find increased expression of receptors in both sensory pathways and innate immune response including TLR4. Higher TLR4 expression was associated with greater urgency. TLR4 expression correlated strongly with the expression of the receptors bradykinin receptor B2, chemerin chemokine-like receptor 1, and transient receptor potential cation channel, subfamily A, member 1 as well as TLR4's downstream adaptor myeloid differentiation factor 88. Mesalazine had minimal effect on either gene expression or microbiota composition.
Biopsies from a well-characterized IBS-D cohort showed no substantial inflammation. Mesalazine has little effect on gene expression and its previous reported effect on fecal microbiota associated with much greater inflammation found in inflammatory bowel diseases is likely secondary to reduced inflammation. Increased expression of TLR4 and correlated receptors in IBS may mediate a general increase in sensitivity to external stimuli, particularly those that signal via the TLR system.
背景/目的:腹泻型肠易激综合征(IBS-D)先前已被证明与免疫激活及微生物群改变有关。我们的目的是评估抗炎药物美沙拉嗪对IBS-D患者炎症基因表达及微生物群组成的影响。
我们研究了先前发表的一项为期12周的美沙拉嗪随机安慰剂对照试验中的一部分患者(n = 43)。在治疗后随机分组时,通过免疫组织化学和逆转录聚合酶链反应对黏膜活检样本进行评估,检测一系列炎症、通透性改变及感觉受体标志物,包括Toll样受体(TLR)。所有活检数据均与21名健康对照进行比较。通过16S核糖体RNA测序分析患者粪便微生物群组成。
与健康对照相比,我们未发现免疫激活增加的证据。然而,我们确实发现感觉通路和固有免疫反应中的受体表达增加,包括TLR4。TLR4表达越高,紧迫性越强。TLR4表达与缓激肽受体B2、趋化素趋化因子样受体1、瞬时受体电位阳离子通道亚家族A成员1以及TLR4的下游衔接蛋白髓样分化因子88的表达密切相关。美沙拉嗪对基因表达或微生物群组成的影响极小。
来自特征明确的IBS-D队列的活检样本未显示明显炎症。美沙拉嗪对基因表达影响很小,其先前报道的对粪便微生物群的影响可能继发于炎症减轻,这种影响在炎症性肠病中更为明显。IBS中TLR4及相关受体表达增加可能介导了对外界刺激敏感性的普遍增加,尤其是那些通过TLR系统发出信号的刺激。